Switch theme
Sign up to access all valuation multiples
Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.
1992
907
LTM Revenue $186M
LTM EBITDA $49.2M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jinyu Bio-Technology Co. has a last 12-month revenue (LTM) of $186M and a last 12-month EBITDA of $49.2M.
In the most recent fiscal year, Jinyu Bio-Technology Co. achieved revenue of $175M and an EBITDA of $48.5M.
Jinyu Bio-Technology Co. expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jinyu Bio-Technology Co. valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $186M | XXX | $175M | XXX | XXX | XXX |
| Gross Profit | $104M | XXX | $94.4M | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $49.2M | XXX | $48.5M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $25.7M | XXX | $20.0M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $22.3M | XXX | $15.2M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Jinyu Bio-Technology Co.'s stock price is CNY 8 (or $1).
Jinyu Bio-Technology Co. has current market cap of CNY 8.8B (or $1.2B), and EV of CNY 7.8B (or $1.1B).
See Jinyu Bio-Technology Co. trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.2B | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Jinyu Bio-Technology Co. has market cap of $1.2B and EV of $1.1B.
Jinyu Bio-Technology Co.'s trades at 6.2x EV/Revenue multiple, and 22.4x EV/EBITDA.
Equity research analysts estimate Jinyu Bio-Technology Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jinyu Bio-Technology Co. has a P/E ratio of 55.2x.
See valuation multiples for Jinyu Bio-Technology Co. and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 5.8x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | 22.1x | XXX | 22.4x | XXX | XXX | XXX |
| EV/EBIT | 42.2x | XXX | 54.2x | XXX | XXX | XXX |
| EV/Gross Profit | 10.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 55.2x | XXX | 80.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 39.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJinyu Bio-Technology Co.'s last 12 month revenue growth is 12%
Jinyu Bio-Technology Co.'s revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Jinyu Bio-Technology Co.'s rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jinyu Bio-Technology Co.'s rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jinyu Bio-Technology Co. and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | -11% | XXX | XXX | XXX |
| Rule of 40 | 44% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jinyu Bio-Technology Co. acquired XXX companies to date.
Last acquisition by Jinyu Bio-Technology Co. was XXXXXXXX, XXXXX XXXXX XXXXXX . Jinyu Bio-Technology Co. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jinyu Bio-Technology Co. founded? | Jinyu Bio-Technology Co. was founded in 1992. |
| Where is Jinyu Bio-Technology Co. headquartered? | Jinyu Bio-Technology Co. is headquartered in China. |
| How many employees does Jinyu Bio-Technology Co. have? | As of today, Jinyu Bio-Technology Co. has 907 employees. |
| Is Jinyu Bio-Technology Co. publicy listed? | Yes, Jinyu Bio-Technology Co. is a public company listed on SHG. |
| What is the stock symbol of Jinyu Bio-Technology Co.? | Jinyu Bio-Technology Co. trades under 600201 ticker. |
| When did Jinyu Bio-Technology Co. go public? | Jinyu Bio-Technology Co. went public in 1999. |
| Who are competitors of Jinyu Bio-Technology Co.? | Similar companies to Jinyu Bio-Technology Co. include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Jinyu Bio-Technology Co.? | Jinyu Bio-Technology Co.'s current market cap is $1.2B |
| What is the current revenue of Jinyu Bio-Technology Co.? | Jinyu Bio-Technology Co.'s last 12 months revenue is $186M. |
| What is the current revenue growth of Jinyu Bio-Technology Co.? | Jinyu Bio-Technology Co. revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Jinyu Bio-Technology Co.? | Current revenue multiple of Jinyu Bio-Technology Co. is 5.8x. |
| Is Jinyu Bio-Technology Co. profitable? | Yes, Jinyu Bio-Technology Co. is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jinyu Bio-Technology Co.? | Jinyu Bio-Technology Co.'s last 12 months EBITDA is $49.2M. |
| What is Jinyu Bio-Technology Co.'s EBITDA margin? | Jinyu Bio-Technology Co.'s last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Jinyu Bio-Technology Co.? | Current EBITDA multiple of Jinyu Bio-Technology Co. is 22.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
